Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 572
Filter
1.
Article in English | MEDLINE | ID: mdl-38701802

ABSTRACT

A 17-year-old Appaloosa mare was referred for evaluation of presumed refractory keratitis of the left eye. Gross examination revealed ocular discomfort and corneal neovascularization with a nasal focal opacification affecting approximately 40% of the corneal surface. On ophthalmic examination, extensive subepithelial to mid-stromal vascular branching accompanied by a homogeneous white, dense opacification, which affected up to 80% of the total corneal thickness, were apparent. Signs of concurrent uveitis were absent. Deep-stromal lamellar keratectomy with a conjunctival pedicle graft was performed under general anesthesia. Histopathology confirmed a poorly differentiated corneal stromal invasive squamous cell carcinoma (SI-SCC) with neoplastic cell extension to the surgical margins. Postoperatively, 4 topical mitomycin C 0.04% chemotherapy cycles combined with oral firocoxib therapy were initiated. Seven months after surgery, regrowth of the SI-SCC was clinically suspected. A total volume of 1 ml bevacizumab 2.5% was administered in the standing sedated horse via 3 mid-stromal corneal injections. Four weeks later, intrastromal bevacizumab injections (ISBIs) were repeated, however, this time the solution was injected directly into the main corneal vessel branches.Seven weeks after the second ISBIs, the left eye was comfortable and significant remission of corneal vascularization and opacity was recognized. No recurrence has been noted for a follow-up period of more than 53 months.Equine SI-SCC usually has a very poor prognosis for globe maintenance. To the authors' knowledge this is the first report of well-tolerated intrastromal antivascular endothelial growth factor adjunctive therapy with bevazicumab 2.5% and SI-SCC resolution after a multimodal treatment approach.


Subject(s)
Bevacizumab , Carcinoma, Squamous Cell , Eye Neoplasms , Horse Diseases , Horses , Animals , Bevacizumab/therapeutic use , Bevacizumab/administration & dosage , Horse Diseases/drug therapy , Female , Carcinoma, Squamous Cell/veterinary , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Eye Neoplasms/veterinary , Eye Neoplasms/drug therapy , Eye Neoplasms/pathology , Eye Neoplasms/surgery , Angiogenesis Inhibitors/therapeutic use , Angiogenesis Inhibitors/administration & dosage , Corneal Stroma/drug effects , Corneal Stroma/pathology
2.
J Control Release ; 369: 604-616, 2024 May.
Article in English | MEDLINE | ID: mdl-38582337

ABSTRACT

Corneal stromal fibrosis is a common cause of visual impairment resulting from corneal injury, inflammation and surgery. Therefore, there is an unmet need for inhibiting corneal stromal fibrosis. However, bioavailability of topical eye drops is very low due to the tear and corneal barriers. In situ delivery offers a unique alternative to improve efficacy and minimize systemic toxicity. Herein, a drug delivery platform based on thermoresponsive injectable hydrogel/nano-micelles composite with in situ drug-controlled release and long-acting features is developed to prevent corneal scarring and reduce corneal stromal fibrosis in lamellar keratoplasty. The in-situ gelation hydrogels enabled direct delivery of celastrol to the corneal stroma. In vivo evaluation with a rabbit anterior lamellar keratoplasty model showed that hydrogel/micelles platform could effectively inhibit corneal stromal fibrosis. This strategy achieves controlled and prolonged release of celastrol in the corneal stroma of rabbit. Following a single corneal interlamellar injection, celastrol effectively alleviated fibrosis via mTORC1 signal promoting autophagy and inhibiting TGF-ß1/Smad2/3 signaling pathway. Overall, this strategy demonstrates promise for the clinical application of celastrol in preventing corneal scarring and reducing corneal stromal fibrosis post-lamellar keratoplasty, highlighting the potential benefits of targeted drug delivery systems in ocular therapeutics.


Subject(s)
Corneal Transplantation , Hydrogels , Pentacyclic Triterpenes , Animals , Rabbits , Pentacyclic Triterpenes/administration & dosage , Hydrogels/administration & dosage , Corneal Transplantation/methods , Cicatrix/prevention & control , Cicatrix/drug therapy , Delayed-Action Preparations , Fibrosis , Drug Delivery Systems , Cornea/drug effects , Cornea/metabolism , Triterpenes/administration & dosage , Drug Liberation , Corneal Stroma/drug effects , Humans
3.
Exp Eye Res ; 242: 109884, 2024 May.
Article in English | MEDLINE | ID: mdl-38570181

ABSTRACT

Recent studies in rabbits and case reports in humans have demonstrated the efficacy of topical losartan in the treatment of corneal scarring fibrosis after a wide range of injuries, including chemical burns, infections, surgical complications, and some diseases. It is hypothesized that the effect of losartan on the fibrotic corneal stroma occurs through a two-phase process in which losartan first triggers the elimination of myofibroblasts by directing their apoptosis via inhibition of extracellular signal-regulated kinase (ERK)-mediated signal transduction, and possibly through signaling effects on the viability and development of corneal fibroblast and fibrocyte myofibroblast precursor cells. This first step likely occurs within a week or two in most corneas with fibrosis treated with topical losartan, but the medication must be continued for much longer until the epithelial basement membrane (EBM) is fully regenerated or new myofibroblasts will develop from precursor cells. Once the myofibroblasts are eliminated from the fibrotic stroma, corneal fibroblasts can migrate into the fibrotic tissue and reabsorb/reorganize the disordered extracellular matrix (ECM) previously produced by the myofibroblasts. This second stage is longer and more variable in different eyes of rabbits and humans, and accounts for most of the variability in the time it takes for the stromal opacity to be markedly reduced by topical losartan treatment. Eventually, keratocytes reemerge in the previously fibrotic stromal tissue to fine-tune the collagens and other ECM components and maintain the normal structure of the corneal stroma. The efficacy of losartan in the prevention and treatment of corneal fibrosis suggests that it acts as a surrogate for the EBM, by suppressing TGF beta-directed scarring of the wounded corneal stroma, until control over TGF beta action is re-established by a healed EBM, while also supporting regeneration of the EBM by allowing corneal fibroblasts to occupy the subepithelial stroma in the place of myofibroblasts.


Subject(s)
Corneal Stroma , Fibrosis , Losartan , Myofibroblasts , Losartan/therapeutic use , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Stroma/pathology , Fibrosis/drug therapy , Humans , Animals , Myofibroblasts/pathology , Myofibroblasts/drug effects , Rabbits , Corneal Diseases/drug therapy , Corneal Diseases/pathology , Angiotensin II Type 1 Receptor Blockers , Administration, Topical
4.
Indian J Ophthalmol ; 72(5): 712-717, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38648433

ABSTRACT

PURPOSE: To compare the changes encountered in corneal biomechanics and aberration profile following accelerated corneal collagen cross-linking (CXL) using hypo-osmolar and iso-osmolar riboflavin in corneal thicknesses of <400 and >400 microns, respectively. METHODS: This is a prospective, interventional, comparative study involving 100 eyes of 75 patients with progressive keratoconus. Eyes were divided into two groups based on corneal thickness: group 1 included eyes with a corneal thickness of <400 microns who underwent hypo-osmolar CXL, and group 2 included eyes with a corneal thickness of >400 microns who underwent iso-osmolar CXL. Corneal biomechanical and aberration profiles were evaluated and compared between groups. RESULTS: In group 1, all higher-order aberrations (HOA) except secondary astigmatism significantly decreased from baseline; however, in group 2, only coma and trefoil decreased. The corneal resistance factor and corneal hysteresis significantly improved in both groups, which was significantly greater in group 2 than in group 1. The change in inverse radius, deformation amplitude, and tomographic biomechanical index was significantly improved in group 2 as compared to group 1. CONCLUSION: Improvement in corrected distance visual acuity and decrease in HOA were significantly better in the hypo-osmolar CXL group; however, the improvement in biomechanical strength of the cornea was significantly better in the iso-osmolar group.


Subject(s)
Collagen , Cornea , Corneal Topography , Cross-Linking Reagents , Keratoconus , Photosensitizing Agents , Riboflavin , Ultraviolet Rays , Visual Acuity , Adolescent , Adult , Female , Humans , Male , Young Adult , Biomechanical Phenomena , Collagen/metabolism , Cornea/diagnostic imaging , Cornea/physiopathology , Cornea/drug effects , Corneal Stroma/metabolism , Corneal Stroma/drug effects , Corneal Wavefront Aberration/physiopathology , Cross-Linking Reagents/therapeutic use , Follow-Up Studies , Keratoconus/drug therapy , Keratoconus/physiopathology , Keratoconus/diagnosis , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Prospective Studies , Refraction, Ocular/physiology , Riboflavin/therapeutic use , Visual Acuity/physiology , Child
5.
Am J Physiol Cell Physiol ; 326(5): C1482-C1493, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38525537

ABSTRACT

Corneal fibroblasts maintain homeostasis of the corneal stroma by mediating the synthesis and degradation of extracellular collagen, and these actions are promoted by transforming growth factor-ß (TGF-ß) and interleukin-1ß (IL-1ß), respectively. The cornea is densely innervated with sensory nerve fibers that are not only responsible for sensation but also required for physiological processes such as tear secretion and wound healing. Loss or dysfunction of corneal nerves thus impairs corneal epithelial wound healing and can lead to neurotrophic keratopathy. The sensory neurotransmitter substance P (SP) promotes corneal epithelial wound healing by enhancing the stimulatory effects of growth factors and fibronectin. We have now investigated the role of SP in collagen metabolism mediated by human corneal fibroblasts in culture. Although SP alone had no effect on collagen synthesis or degradation by these cells, it promoted the stimulatory effect of TGF-ß on collagen type I synthesis without affecting that of IL-1ß on the expression of matrix metalloproteinase-1. This effect of SP on TGF-ß-induced collagen synthesis was accompanied by activation of p38 mitogen-activated protein kinase (MAPK) signaling and was attenuated by pharmacological inhibition of p38 or of the neurokinin-1 receptor. Our results thus implicate SP as a modulator of TGF-ß-induced collagen type I synthesis by human corneal fibroblasts, and they suggest that loss of this function may contribute to the development of neurotrophic keratopathy.NEW & NOTEWORTHY This study investigates the role of substance P (SP) in collagen metabolism mediated by human corneal fibroblasts in culture. We found that, although SP alone had no effect on collagen synthesis or degradation by corneal fibroblasts, it promoted the stimulatory effect of transforming growth factor-ß on collagen type I synthesis without affecting that of interleukin-1ß on the expression of matrix metalloproteinase-1.


Subject(s)
Fibroblasts , Interleukin-1beta , Substance P , Transforming Growth Factor beta , p38 Mitogen-Activated Protein Kinases , Humans , Substance P/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Transforming Growth Factor beta/metabolism , Fibroblasts/metabolism , Fibroblasts/drug effects , Cells, Cultured , Interleukin-1beta/metabolism , Collagen Type I/metabolism , Collagen Type I/biosynthesis , Receptors, Neurokinin-1/metabolism , Cornea/metabolism , Cornea/drug effects , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 1/genetics , Collagen/metabolism , Collagen/biosynthesis , Signal Transduction/drug effects , Corneal Stroma/metabolism , Corneal Stroma/drug effects , Corneal Keratocytes/metabolism , Corneal Keratocytes/drug effects
6.
Graefes Arch Clin Exp Ophthalmol ; 262(6): 1847-1855, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38133799

ABSTRACT

BACKGROUND: Corneal tissues indirectly obtain nutritional needs and oxygen to maintain their homeostasis, and therefore, benzalkonium chloride (BAC) containing ocular instillations for medical therapy may, in turn, induce toxic effects more than expected in corneal tissues, especially the inside stroma layer. METHODS: To evaluate the effects of very low concentrations (10-8%, 10-6%, or 10-4%) of BAC on human corneal stroma, we used two-dimensional (2D) cultures of human corneal stromal fibroblast (HCSF) cells and carried out the following analyses: (1) cell viability measurements, (2) Seahorse cellular bio-metabolism analysis, and (3) the expression of ECM molecules and endoplasmic reticulum (ER) stress-related molecules. RESULTS: In the absence and presence of 10-8%, 10-6%, or 10-4% concentrations of BAC, cell viability deteriorated and this deterioration was dose-dependent. The results showed that maximal mitochondrial respiration was decreased, the mRNA expression of most of ECM proteins was decreased, and ER stress-related molecules were substantially and dose-dependently down-regulated in HCSFs by the BAC treatment. CONCLUSIONS: The findings reported herein indicate that the presence of BAC, even at such low concentrations, is capable of causing the deterioration of cellular metabolic functions and negatively affecting the response to ER stress in HCSF cells resulting in a substantially decreased cellular viability.


Subject(s)
Benzalkonium Compounds , Cell Survival , Corneal Stroma , Preservatives, Pharmaceutical , Humans , Benzalkonium Compounds/toxicity , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Cell Survival/drug effects , Cells, Cultured , Preservatives, Pharmaceutical/toxicity , Dose-Response Relationship, Drug , Endoplasmic Reticulum Stress/drug effects , Fibroblasts/drug effects , Fibroblasts/metabolism , Corneal Keratocytes/drug effects , Corneal Keratocytes/metabolism , Real-Time Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Messenger/metabolism
7.
Cornea ; 41(4): 456-461, 2022 Apr 01.
Article in English | MEDLINE | ID: mdl-35244626

ABSTRACT

PURPOSE: The purpose of this study was to assess an intellectual disability (ID) cohort with keratoconus (KC) regarding ophthalmic (visual acuity and corneal tomography) and systemic characteristics and to describe an appropriate clinical algorithm for investigation and management of KC in this setting. METHODS: This was the retrospective cohort study of patients with ID (Down syndrome, autism, and other) in the cornea department of a tertiary referral ophthalmic hospital in Dublin, Ireland. Retrospective chart review was conducted on people with ID undergoing examination under anesthesia or crosslinking under general anesthetic. Key outcome data included corneal examination findings, corneal tomography, visual acuity, and examination findings (eg, type of ID, general anesthetic, and cardiac status). RESULTS: Mean age of the 24 patients was 31.9 years (66.7% male). ID type was Down syndrome (66.7%), autism (25%), and other (8.3%). KC was diagnosed in 98% of eyes, with 45.8% having untreatable advanced disease (57.1% of these bilateral), 39.6% amenable to corneal collagen crosslinking (35.7% of these bilateral), and 6.3% having corneal transplantation. Congenital heart defects were present in 37.5% of the Down syndrome group. There were no serious ocular or systemic adverse events. CONCLUSIONS: KC is strikingly prevalent in the ID population. Ireland has the highest rate of Down syndrome in Europe (26.3:10,000 live births). This group is rarely suitable for corneal transplantation, and corneal collagen crosslinking is an effective intervention to prevent progression to advanced KC in this already socially restricted group. We propose an algorithm for investigation/treatment and also recommend uniform pediatric KC screening/treatment in ID populations.


Subject(s)
Autism Spectrum Disorder/complications , Corneal Transplantation , Cross-Linking Reagents/therapeutic use , Down Syndrome/complications , Intellectual Disability/complications , Keratoconus/therapy , Adolescent , Adult , Child , Collagen/metabolism , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Topography , Female , Follow-Up Studies , Humans , Keratoconus/drug therapy , Keratoconus/physiopathology , Keratoconus/surgery , Male , Middle Aged , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Retrospective Studies , Riboflavin/therapeutic use , Ultraviolet Rays , Visual Acuity/physiology , Young Adult
8.
Cornea ; 41(4): 470-477, 2022 Apr 01.
Article in English | MEDLINE | ID: mdl-35244627

ABSTRACT

PURPOSE: The aim of this study was to explore the optimal method of small-incision lenticule extraction (SMILE)-derived lenticules, subjected to long-term preservation using glycerol, under a range of temperatures, and using an array of dehydration agents. METHODS: In total, 108 myopic lenticules were collected from patients undergoing the SMILE procedure. Fresh lenticules served as a control group for this study, whereas all other lenticules were separated into 8 groups, which were preserved at 4 different temperatures (room temperature [RT], 4, -20, and -80°C) with or without silica gel in anhydrous glycerol. Evaluated parameters included thickness, transmittance, hematoxylin and eosin staining, transmission electron microscopy, and immunohistochemistry analyses. RESULTS: After a 3-month preservation period, lenticular thickness in these different groups was significantly increased, particularly for samples stored at RT. The mean percentage transmittance of lenticules stored at -80°C with or without silica gel was closest to that of fresh lenticules. Hematoxylin and eosin staining revealed sparsely arranged collagen fibers that were more scattered in preserved lenticules relative to fresh lenticules, particularly in RT samples. Transmission electron microscopy revealed that the fibril bundles densities in lenticules stored at RT were significantly less than those stored at other temperatures. Immunohistochemistry analyses revealed reductions in or loss of CD45 and human leukocyte antigens in all preserved lenticules relative to control samples. CONCLUSIONS: Of the tested approaches, the preservation of SMILE-derived lenticules over a 3-month period was optimal at -80°C with or without silica gel in anhydrous glycerol.


Subject(s)
Corneal Stroma/drug effects , Corneal Surgery, Laser/methods , Cryoprotective Agents/pharmacology , Desiccation/methods , Glycerol/pharmacology , Myopia/surgery , Temperature , Adult , Corneal Stroma/physiology , HLA Antigens/metabolism , HLA-DR Antigens/metabolism , Humans , Leukocyte Common Antigens/metabolism , Microscopy, Electron, Transmission , Tissue Preservation/methods , Tissue and Organ Harvesting
9.
Cornea ; 41(4): 408-416, 2022 Apr 01.
Article in English | MEDLINE | ID: mdl-33859086

ABSTRACT

PURPOSE: The aim of this study was to assess the effect of corneal crosslinking on vision and keratometry in children and young adults with progressive keratoconus. METHODS: A retrospective medical records review of patients aged 22 years or younger with keratoconus who underwent corneal crosslinking between January 2013 and November 2019 at Byers Eye Institute at Stanford University was conducted. Outcome measures included logarithm of the Minimum Angle of Resolution corrected distance visual acuity (CDVA); keratometry, including maximum keratometry (Kmax); pachymetry; and total wavefront aberration. Measurements were taken at baseline and at 12 and 24 months postoperatively. RESULTS: Fifty-seven eyes of 49 patients aged 12 to 22 years were assessed. The mean preoperative CDVA was logarithm of the Minimum Angle of Resolution 0.38 ± 0.32 (20/48), with a mean postoperative CDVA of 0.29 ± 0.31 (20/39) and 0.31 ± 0.31 (20/41) at 12 and 24 months postoperatively, respectively. Compared with preoperative mean Kmax, there was an improvement of -0.8 diopters (D) to a mean postoperative Kmax of 59.1 ± 9.1 D at 12 months and -1.3 D to 59.7 ± 8.8 D at 24 months. Subanalysis excluding the second eye of patients who underwent bilateral crosslinking showed similar results. Linear mixed modeling showed significant improvement in Kmax at both 12 and 24 months postoperatively. Minimum central corneal thickness initially decreased but stabilized at 24 months after crosslinking. Total wavefront aberration remained stable. CONCLUSIONS: Corneal crosslinking stabilizes, and in some cases improves, visual and corneal parameters in pediatric and young adult patients with keratoconus. The procedure is safe and well-tolerated and may prevent keratoconus progression in young patients.


Subject(s)
Collagen/metabolism , Cross-Linking Reagents/therapeutic use , Keratoconus/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Riboflavin/therapeutic use , Adolescent , Child , Corneal Pachymetry , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Topography , Female , Humans , Keratoconus/metabolism , Keratoconus/physiopathology , Male , Retrospective Studies , Treatment Outcome , Ultraviolet Rays , Visual Acuity/physiology , Young Adult
10.
Exp Eye Res ; 214: 108839, 2022 01.
Article in English | MEDLINE | ID: mdl-34785203

ABSTRACT

PURPOSE: To explore the effect of age on corneal biomechanical properties following corneal cross-linking (CXL). METHODS: A total of 12 pairs of human eye-banked corneas (24 corneas, from 14 females and 10 males) were used in the study. The mean donor age was 48.5 years (ranging from 26 to 71 years). Corneas were divided into three age groups: A (26-41 years), B (42-57 years) and C (58-71 years), with four pairs in each group. For each pair, the right corneas were cross-linked using accelerated CXL with UVA (10 mW/cm2) and riboflavin, while the left corneas served as controls and were not exposed to either UVA irradiation or riboflavin. The corneal elastic modulus of the anterior, mid and posterior corneal stroma was measured using nanoindentation. RESULTS: The difference in the corneal elastic modulus following CXL was significant in the anterior (p = 0.00002) and mid stroma (p = 0.001); however, the difference was not significant in the posterior stroma (p = 0.27) when compared to control corneas. The corneal elastic modulus of the anterior stroma increased by 178.44% in Group A, 119.7% in Group B and 50.73% in Group C compared to control corneas. For the mid stroma, the elastic modulus increased by 47.35% in Group A, 25% in Group B and 24.56% in Group C. No differences were observed in the posterior stroma between age groups. CONCLUSIONS: Corneal elasticity showed a greater response to CXL in the younger group compared to older groups. CXL treatment showed effectiveness in enhancing stromal strength, and the effect was concentrated in the anterior and mid stroma with minimal impact on the posterior stroma in all age groups.


Subject(s)
Aging/physiology , Collagen/metabolism , Cornea/physiology , Cross-Linking Reagents/pharmacology , Elastic Modulus/physiology , Adult , Aged , Biomechanical Phenomena , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Female , Humans , Keratoconus/drug therapy , Keratoconus/metabolism , Keratoconus/physiopathology , Male , Middle Aged , Photochemotherapy/methods , Photosensitizing Agents/pharmacology , Riboflavin/pharmacology , Ultraviolet Rays
11.
Cornea ; 41(4): 462-469, 2022 Apr 01.
Article in English | MEDLINE | ID: mdl-34743098

ABSTRACT

PURPOSE: The aim of this study was to compare the 4-year clinical outcomes of transepithelial diluted alcohol and iontophoresis-assisted corneal crosslinking (DAI-CXL) and standard corneal crosslinking (S-CXL) in adults with progressive keratoconus. METHODS: This retrospective study included 36 eyes of 36 keratoconic patients who underwent DAI-CXL (n = 18) or S-CXL (n = 18). Best spectacle-corrected visual acuity (BSCVA) and corneal topography parameters were analyzed at baseline and at 1, 2, 3, and 4 years of follow-up. Corneal demarcation line depth (DLD) at 1 month was measured, and the relation of DLD with corneal thickness (DL%) was assessed. RESULTS: BSCVA improved significantly only in S-CXL (P = 0.01). A significant decrease in maximum keratometry and mean keratometry occurred at 4 years in both groups (all P < 0.05), and these changes were similar in both groups (all P > 0.05). There was a significant reduction in the thinnest corneal thickness in S-CXL (P = 0.01); however, the mean thinnest corneal thickness in DAI-CXL remained stable (P = 0.094). Higher-order aberrations and coma aberration decreased significantly in both groups at 4 years (all P < 0.05), with a higher decrease in S-CXL (all P < 0.05). Spherical aberration showed a significant reduction only in S-CXL (P = 0.005). In contrast to the similar mean DLD in both groups, DL% in DAI-CXL was significantly greater than that in S-CXL (P = 0.032). There were no correlations between the improvement in BSCVA, maximum keratometry, mean keratometry, higher-order aberrations, and the mean DLD and DL% (all P > 0.05). CONCLUSIONS: DAI-CXL was as effective as S-CXL in arresting the progression of keratoconus and showed similar clinical results to S-CXL at the 4-year follow-up.


Subject(s)
Cross-Linking Reagents/therapeutic use , Epithelium, Corneal/drug effects , Ethanol/administration & dosage , Iontophoresis/methods , Keratoconus/drug therapy , Photosensitizing Agents/therapeutic use , Adult , Collagen/metabolism , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Topography , Female , Humans , Keratoconus/metabolism , Keratoconus/physiopathology , Male , Photochemotherapy/methods , Retrospective Studies , Riboflavin/therapeutic use , Ultraviolet Rays , Visual Acuity/physiology , Young Adult
12.
Cornea ; 40(10): 1322-1329, 2021 Oct 01.
Article in English | MEDLINE | ID: mdl-34481408

ABSTRACT

PURPOSE: To evaluate the ABCD grading system in pediatric keratoconus. METHODS: A retrospective cohort analysis of all children with keratoconus followed up at the Shamir medical center between 2010 and 2017. A recommendation by the treating physician to undergo corneal crosslinking (CXL) was used as an estimate for clinically significant disease progression. The ABCD grading was not available to the treating physician and was computed post hoc. The ABCD grading was compared between patients who required CXL with those who did not. A single eye of each patient was included. RESULTS: Fifty eyes of 50 children were analyzed. The mean age at presentation was 15.56 ± 1.36 years. In 23 eyes, progression of keratoconus was recorded and CXL was performed (CXL-group). On presentation, the stable and CXL groups did not differ significantly in their clinical parameters. In the CXL-group, a statistically significant increase was seen in the ABCD staging (P < 0.001). In the stable group, the ABCD staging did not change significantly in parallel visits (P = 0.87). An increase of 1 point in the sum of the ABCD staging showed a 5-fold risk for undergoing CXL (odds ratio = 5.28; 95% CI, 1.82-15.34). There was no significant change in the Amsler-Krumeich classification in the CXL group. CONCLUSIONS: Among a cohort of pediatric patients with keratoconus, worsening in the ABCD grading was associated with disease progression, whereas no significant change was demonstrated in the Amsler-Krumeich classification The ABCD grading system is a useful tool for initial assessment of disease progression in the pediatric population, in which early recognition is of paramount importance.


Subject(s)
Diagnostic Techniques, Ophthalmological , Keratoconus/classification , Keratoconus/diagnosis , Adolescent , Collagen/metabolism , Corneal Pachymetry , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Cross-Linking Reagents/therapeutic use , Disease Progression , Female , Humans , Keratoconus/drug therapy , Male , Photochemotherapy , Photosensitizing Agents/therapeutic use , Retrospective Studies , Ultraviolet Rays , Visual Acuity/physiology
14.
Exp Eye Res ; 211: 108747, 2021 10.
Article in English | MEDLINE | ID: mdl-34450184

ABSTRACT

PURPOSE: Cornea epithelial-stromal scarring is related to the differentiation of fibroblasts into opaque myofibroblasts. Our study aims to assess the effectiveness of Lycium barbarum polysaccharide (LBP) solution as a pre-treatment in minimizing corneal scarring. METHODS: Human corneal fibroblasts were cultured in a three-dimensional collagen type I-based hydrogel in an eye-on-a-chip model. Fibroblasts were pre-treated with 2 mg/mL LBP for 24 h, followed by another 24-h incubation with 10 ng/mL transforming growth factor-beta 1 (TGF-ß1) to induce relevant physiological events after stromal injury. Intracellular pro-fibrotic proteins, extracellular matrix proteins, and pro-inflammatory cytokines that involved in fibrosis, were assessed using immunocytochemistry and enzyme-linked immunosorbent assays. RESULTS: Compared to the positive control TGF-ß1 group, LBP pre-treated cells had a significantly lower expression of alpha-smooth muscle actin, marker of myofibroblasts, vimentin (p < 0.05), and also extracellular matrix proteins both collagen type II and type III (p < 0.05) that can be found in scar tissues. Moreover, LBP pre-treated cells had a significantly lower secretion of pro-inflammatory cytokines interleukin-6 and interleukin-8 (p < 0.05). The cell-laden hydrogel contraction and stiffness showed no significant difference between LBP pre-treatment and control groups. Fibroblasts pretreated with LBP as well had reduced angiogenic factors expression and suppression of undesired proliferation (p < 0.05). CONCLUSION: Our results showed that LBP reduced both pro-fibrotic proteins and pro-inflammatory cytokines on corneal injury in vitro. We suggest that LBP, as a natural Traditional Chinese Medicine, may potentially be a novel topical pre-treatment option prior to corneal refractive surgeries with an improved prognosis.


Subject(s)
Cicatrix/prevention & control , Corneal Diseases/prevention & control , Corneal Stroma/drug effects , Drugs, Chinese Herbal/therapeutic use , Epithelium, Corneal/drug effects , Actins/metabolism , Administration, Ophthalmic , Biomarkers/metabolism , Cicatrix/metabolism , Corneal Diseases/metabolism , Corneal Keratocytes/drug effects , Corneal Keratocytes/metabolism , Corneal Stroma/metabolism , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Epithelium, Corneal/metabolism , Extracellular Matrix Proteins/metabolism , Humans , Immunohistochemistry , Medicine, Chinese Traditional , Ophthalmic Solutions , Transforming Growth Factor beta1/pharmacology
15.
Elife ; 102021 06 04.
Article in English | MEDLINE | ID: mdl-34085926

ABSTRACT

Disorders of the transparent cornea affect millions of people worldwide. However, how to maintain and/or regenerate this organ remains unclear. Here, we show that Rela (encoding a canonical NF-κB subunit) ablation in K14+ corneal epithelial stem cells not only disrupts corneal regeneration but also results in age-dependent epithelial deterioration, which triggers aberrant wound-healing processes including stromal remodeling, neovascularization, epithelial metaplasia, and plaque formation at the central cornea. These anomalies are largely recapitulated in normal mice that age naturally. Mechanistically, Rela deletion suppresses expression of Aldh1a1, an enzyme required for retinoic acid synthesis from vitamin A. Retinoic acid administration blocks development of ocular anomalies in Krt14-Cre; Relaf/f mice and naturally aged mice. Moreover, epithelial metaplasia and plaque formation are preventable by inhibition of angiogenesis. This study thus uncovers the major mechanisms governing corneal maintenance, regeneration, and aging and identifies the NF-κB-retinoic acid pathway as a therapeutic target for corneal disorders.


Subject(s)
Burns, Chemical/drug therapy , Cellular Senescence/drug effects , Corneal Neovascularization/prevention & control , Epithelium, Corneal/drug effects , Eye Burns/drug therapy , Regeneration/drug effects , Stem Cells/drug effects , Transcription Factor RelA/metabolism , Tretinoin/pharmacology , Age Factors , Aldehyde Dehydrogenase 1 Family/genetics , Aldehyde Dehydrogenase 1 Family/metabolism , Animals , Burns, Chemical/etiology , Burns, Chemical/metabolism , Burns, Chemical/pathology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Corneal Neovascularization/metabolism , Corneal Neovascularization/pathology , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Stroma/pathology , Disease Models, Animal , Epithelium, Corneal/metabolism , Epithelium, Corneal/pathology , Eye Burns/chemically induced , Eye Burns/metabolism , Eye Burns/pathology , Mice, Knockout , Retinal Dehydrogenase/genetics , Retinal Dehydrogenase/metabolism , Signal Transduction , Stem Cells/metabolism , Stem Cells/pathology , Transcription Factor RelA/genetics
16.
Cornea ; 40(7): 917-920, 2021 Jul 01.
Article in English | MEDLINE | ID: mdl-34086008

ABSTRACT

PURPOSE: To report a case of diffuse lamellar keratitis (DLK) after corneal collagen cross-linking in an eye with a remote history of laser in situ keratomileusis (LASIK) surgery. METHODS: This is a case report and literature review. RESULTS: This report describes the development of unilateral stage IV DLK in a patient who underwent bilateral corneal cross-linking for corneal ectasia 18 years after LASIK surgery. The patient was treated with high-dose topical steroids that were tapered over 1 month and multiple flap lifts. The ultimate best-corrected visual outcome was 20/60. CONCLUSIONS: DLK is a potential sight-threatening complication of refractive surgery that can occur at any time in the postoperative period, even years after the procedure. Undergoing a subsequent corneal procedure that may disrupt or promote inflammation within the surgical flap-stromal interface, such as corneal collagen cross-linking, is a recognized risk factor for the development of DLK. This case suggests that patients with any history of LASIK surgery undergoing corneal cross-linking or other lamellar corneal surgeries may benefit from closer follow-up (eg, daily) than patients with no history of LASIK.


Subject(s)
Collagen/metabolism , Corneal Stroma/drug effects , Cross-Linking Reagents/adverse effects , Keratitis/etiology , Keratomileusis, Laser In Situ , Photochemotherapy/adverse effects , Corneal Stroma/metabolism , Dilatation, Pathologic/surgery , Female , Humans , Lasers, Excimer , Middle Aged , Photosensitizing Agents/adverse effects , Riboflavin/adverse effects , Time Factors , Ultraviolet Rays
17.
Cornea ; 40(9): 1181-1187, 2021 Sep 01.
Article in English | MEDLINE | ID: mdl-34050067

ABSTRACT

PURPOSE: The aim of this study was to report novel ray-tracing customization of surface excimer laser ablation combined with higher fluence corneal crosslinking (CXL) in the stabilization and normalization of ectasia and visual rehabilitation of progressive keratoconus. METHODS: A 28-year-old man with bilateral progressive keratoconus was treated with Athens protocol: CXL combined with photorefractive surface ablation customized by a novel artificial intelligence platform calculating lower- and higher-order aberrations based on wavefront, Scheimpflug tomography, and interferometry axial length data from a single diagnostic device. Visual acuity, refractive error, keratometry, optical coherence tomography and Scheimpflug tomography, and endothelial cell density were evaluated over 12 months. RESULTS: Keratoconus stabilized in both eyes. Uncorrected distance visual acuity changed from 20/80 to 20/20 in the OD and from 20/40 to 20/25 in the OS at 12 months. Keratometry changes were as follows: from 40.7 and 42.7 at 165.1 degrees to 41.4 and 43.1 at 169.3 degrees in the OD and from 40.9 and 42.6 at 15.9 degrees to 44.1 and 44.7 at 9.8 degrees in the OS. Corneal surface normalization was as follows: index of height decentration from 0.115 to 0.099 and index of surface variance from 77 to 67 in the OD and index of height decentration from 0.066 to 0.014 and index of surface variance from 49 to 31 in the OS. CONCLUSIONS: We introduced in this study the management of progressive keratoconus with CXL combined with novel excimer laser customization using several independent up-to-now diagnostics calculated by software, evaluating bidirectional theoretical ray tracing. It bears the potential advantage of addressing more accurately normalization of the distorted human eye optics associated with corneal ectasia, compared with using anterior corneal surface data or wavefront data alone.


Subject(s)
Cross-Linking Reagents/therapeutic use , Keratoconus/therapy , Photochemotherapy/methods , Photorefractive Keratectomy/methods , Photosensitizing Agents/therapeutic use , Riboflavin/therapeutic use , Adult , Artificial Intelligence , Collagen/metabolism , Combined Modality Therapy , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Topography , Humans , Keratoconus/drug therapy , Keratoconus/metabolism , Keratoconus/surgery , Lasers, Excimer , Male , Prospective Studies , Refraction, Ocular/physiology , Ultraviolet Rays , Visual Acuity/physiology
18.
Sci Rep ; 11(1): 8647, 2021 04 21.
Article in English | MEDLINE | ID: mdl-33883646

ABSTRACT

Corneal neovascularization (CNV) causes higher-order aberrations, corneal edema, ocular inflammation, and corneal transplant rejection, thereby decreasing visual acuity. In this study, we investigated the effects of topical administration of the kappa opioid receptor agonist nalfurafine (TRK-820) on CNV. To induce CNV, intrastromal corneal sutures were placed on the corneal stroma of BALB/c mice for 2 weeks. Nalfurafine (0.1 µg/2 µL/eye) was topically administered to the cornea once or twice daily after CNV induction. The CNV score, immune cell infiltration, and mRNA levels of angiogenic and pro-inflammatory factors in neovascularized corneas were evaluated using slit-lamp microscopy, immunohistochemistry, flow cytometry, and polymerase chain reaction. The mRNA expression of the kappa opioid receptor gene Oprk1 was significantly upregulated following CNV induction. Topical administration of nalfurafine twice daily significantly suppressed CNV and lymphangiogenesis, as well as reduced the mRNA levels of angiogenic and pro-inflammatory factors in the neovascularized corneas. Moreover, nalfurafine administration twice daily reduced the numbers of infiltrating leukocytes, neutrophils, macrophages, and interferon-γ-producing CD4+ T cells in the neovascularized corneas. In this study, we demonstrated that topical administration of nalfurafine suppressed local CNV in a mouse model along with the activation of KOR, suggesting that nalfurafine may prevent and control CNV in humans.


Subject(s)
Corneal Neovascularization/drug therapy , Corneal Stroma/drug effects , Inflammation/drug therapy , Morphinans/administration & dosage , Receptors, Opioid, kappa/agonists , Spiro Compounds/administration & dosage , Administration, Topical , Animals , Corneal Edema/drug therapy , Corneal Edema/metabolism , Corneal Neovascularization/metabolism , Corneal Stroma/metabolism , Gene Expression/drug effects , Inflammation/metabolism , Macrophages/drug effects , Macrophages/metabolism , Male , Mice , Mice, Inbred BALB C , Neutrophils/drug effects , RNA, Messenger/metabolism
19.
Optom Vis Sci ; 98(4): 350-354, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33852551

ABSTRACT

SIGNIFICANCE: The development of confocal microscopy allows one to obtain high-resolution corneal images like its optical density. Some studies have evaluated the optical density with Scheimpflug cameras in the early post-operative period after photorefractive keratectomy, but no studies have evaluated the long-term evolution of optical density after surface ablation when mitomycin C is used. PURPOSE: This work aimed to study the changes in corneal optical density measured with confocal microscopy in eyes treated with laser-assisted subepithelial keratectomy (LASEK) and intraoperative mitomycin C (MMC) to correct myopia. METHODS: A study of 24 consecutive myopic eyes that underwent LASEK with 0.02% MMC and a control group of 24 healthy nontreated eyes was performed. Optical density was measured using the images by the confocal microscopy of the Heidelberg Retina Tomograph II with the Rostock Cornea Module. An analysis of confocal microscopy images was performed using the ImageJ software to obtain the optical density, in gray-scale units (GSU). The optical density of the stromal bed was evaluated 3 months, 15 months, and 3 years after surgery and was compared with the optical density at the equivalent depth of the stroma in controls. RESULTS: The mean values of optical density for the LASEK group were 81.7 ± 9.7, 78.6 ± 11.7, and 73.6 ± 18.7 GSU at 3 months, 15 months, and 3 years, respectively, and it was 61.8 ± 8.2 GSU for the control group. A statistically higher optical density 3 and 15 months after LASEK with MMC was found compared with controls (P < .001). No significant difference was found in optical density at 3 years post-operatively. CONCLUSIONS: Our study suggests that, after LASEK with MMC, the anterior corneal stroma has a higher optical density at 3 and 15 months post-operatively, which gradually returns to normal values 3 years after surgery.


Subject(s)
Alkylating Agents/administration & dosage , Cornea/physiopathology , Keratectomy, Subepithelial, Laser-Assisted/methods , Lasers, Excimer/therapeutic use , Mitomycin/administration & dosage , Myopia/surgery , Refraction, Ocular/physiology , Adult , Biometry , Combined Modality Therapy , Cornea/diagnostic imaging , Cornea/drug effects , Corneal Stroma/diagnostic imaging , Corneal Stroma/drug effects , Corneal Stroma/physiopathology , Female , Humans , Male , Microscopy, Confocal , Middle Aged , Myopia/diagnostic imaging , Myopia/physiopathology , Prospective Studies , Young Adult
20.
Ophthalmic Genet ; 42(3): 360-363, 2021 06.
Article in English | MEDLINE | ID: mdl-33858272

ABSTRACT

Background: Clinical studies suggest the importance of genetic components in the etiology of keratoconus. However, the contributing genes and variants remain elusive. We present a case of bilateral keratoconus in a child with partial trisomy 13, with a trisomic region spanning loci that have been associated with keratoconus.Materials and Methods: This is a single, retrospective case report of a child with a molecular diagnosis of partial trisomy 13, who was diagnosed with bilateral keratoconus for which at the age of 11 years, she underwent successive epithelium-off corneal cross-linking (CXL) procedures in both eyes, followed by temporary central tarsorrhaphy under general anesthesia.Results: Patient's molecular diagnosis was 70 Megabase trisomic region 13q14.11q34. Pre CXL pachymetry was 426 µm and 496 µm, maximum K values were 52.28 D and 55.45 D in right and left eyes, respectively; at last follow up (12 months post-op) these were 494 µm and 509 µm for pachymetry and maximum K values 50.50 D and 52.43 D in the right and left eyes, respectively. No signs of progression were detected.Conclusion: To the best of our knowledge, this is the first case report to document bilateral keratoconus in a child with partial trisomy 13, in whom successful epithelium-off CXL was achieved with general anesthesia. We emphasize the importance of screening, early diagnosis, and therapy of this treatable but rare cause of decreased vision in partial trisomy 13 patients.


Subject(s)
Keratoconus/genetics , Trisomy 13 Syndrome/genetics , Trisomy/genetics , Child , Collagen/metabolism , Corneal Pachymetry , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Topography , Cross-Linking Reagents/therapeutic use , Female , Follow-Up Studies , Humans , Keratoconus/diagnostic imaging , Keratoconus/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Retrospective Studies , Riboflavin/therapeutic use , Tomography, Optical Coherence , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...